Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts

Open access
Mayo, Rebeca, Crespo, Javier, Martínez‐Arranz, Ibon, Banales, Jesus M, Arias, Mayte, Mincholé, Itziar, Aller de la Fuente, Rocío, Jimenez‐Agüero, Raúl, Alonso, Cristina, de Luis, Daniel A., Vitek, Libor, Stritesky, Jan, Caballería, Joan, Romero‐Gómez, Manuel, Martín‐Duce, Antonio, Mugüerza Huguet, Jose Maria, Busteros‐Moraza, José Ignacio, Idowu, Michael O., Castro, Azucena, Martínez‐Chantar, M. Luz, Ortiz, Pablo, Bruha, Radan, Lu, Shelly C., Bedossa, Pierre, Noureddin, Mazen, Sanyal, Arun J., Mato, José M. · 2018 · Hepatology Communications

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). While liver biopsy is the reference gold standard for NAFLD diagnosis and staging, it has limitations due to its sampling variability, invasive nature, and high cost. Thus, there is a need for noninvasive biomarkers that are robust, reliable, and cost effective. In this study, we measured 540 lipids and amino acids in serum samples from biopsy‐proven subjects with normal liver (NL), NAFL, and NASH. Using logistic regression analysis, we identified two panels of triglycerides that could first discriminate between NAFLD and NL and second between NASH and NAFL. These noninvasive tests were compared to blinded histology as a reference standard. We performed these tests in an original cohort of 467 patients with NAFLD (90 NL, 246 NAFL, and 131 NASH) that was subsequently validated in a separate cohort of 192 patients (7 NL, 109 NAFL, 76 NASH). The diagnostic performances of the validated tests showed an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.88 ± 0.05, 0.94, and 0.57, respectively, for the discrimination between NAFLD and NL and 0.79 ± 0.04, 0.70, and 0.81, respectively, for the discrimination between NASH and NAFL. When the analysis was performed excluding patients with glucose levels >136 mg/dL, the area under the receiver operating characteristic curve for the discrimination between NASH and NAFL increased to 0.81 ± 0.04 with sensitivity and specificity of 0.73 and 0.80, respectively. Conclusion: The assessed noninvasive lipidomic serum tests distinguish between NAFLD and NL and between NASH and NAFL with high accuracy. (Hepatology Communications 2018;2:807‐820)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1188

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Mayo, R., Crespo, J., Martínez‐Arranz, I., Banales, J. M., Arias, M., Mincholé, I., Aller de la Fuente, R., Jimenez‐Agüero, R., Alonso, C., de Luis, D. A., Vitek, L., Stritesky, J., Caballería, J., Romero‐Gómez, M., Martín‐Duce, A., Mugüerza Huguet, J. M., Busteros‐Moraza, J. I., Idowu, M. O., Castro, A., Martínez‐Chantar, M. L., Ortiz, P., Bruha, R., Lu, S. C., Bedossa, P., Noureddin, M., Sanyal, A. J., & Mato, J. M.
Venue
Hepatology Communications
Published
2018-05-04
Volume
2
Issue
7
Pages
807-820
ISSN
2471-254X (ISSN-L)
OpenAlex
W2801297606
Cited by
164
References
9
FWCI
10.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.